Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554602 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL4693020 | 0.84 | TDP1 (0.50) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL19972044 | 0.84 | TDP1 (0.49) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL28811434 | 0.83 | TDP1 (0.51) | TDP1L3MBTL1TSHRALDH1A1LMNA | |
| Hydrogen Sulfide SCHEMBL28004578 | 0.82 | TDP1 (0.70) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL17820543 | 0.81 | L3MBTL1 (0.51) | TDP1L3MBTL1TSHRMAPTALDH1A1 | |
| SCHEMBL4099183 | 0.80 | TDP1 (0.49) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL15869336 | 0.79 | TDP1 (0.66) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL7678865 | 0.79 | TDP1 (0.66) | TDP1L3MBTL1TSHRGPR35MAPT | |
| SCHEMBL2081199 | 0.79 | TDP1 (0.66) | TDP1L3MBTL1TSHRGPR35MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063469-A | Cycloalkenyl-pyridine group-containing compound | 正大天晴药业集团股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114644638-B | Nitrogen-containing heterocyclic compound and application thereof | 广州华睿光电材料有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-114685458-B | Organic compound and application thereof | 广州华睿光电材料有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-114621237-B | Organic compounds, mixtures, compositions and organic electronic devices | 广州华睿光电材料有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-2924021-B1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | UNIV SICHUAN (CN) | 2019-08-28 | — | — | EP | disclosed |
| US-9402819-B2 | Anti-HIV compound and preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-08-02 | — | — | US | disclosed |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-11-05 | — | — | US | disclosed |
| EP-2924021-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan University (CN) | 2015-09-30 | — | — | EP | disclosed |
| CN-102924314-B | Preparation method of 2-amino-6-nitrobenzoic acid | LIANHE CHEMICAL TECHNOLOGY CO LTD | 2015-02-25 | — | — | CN | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-4473650-A | Use of strong organic acid polyelectrolyte salts in test means, test device and method for determining the ionic strength or specific gravity of a liquid sample | MILES LABORATORIES, INC. (US) | 1984-09-25 | — | — | US | disclosed |
| US-4421516-A | Process for preparing discharge resist prints on hydrophobic textile materials | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-12-20 | — | — | US | disclosed |
| EP-0088996-A1 | Process for the production of discharge resist prints on hydrophobic textile materials | CASSELLA Aktiengesellschaft (DE) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | TDP1 2393/4885L3MBTL1 1747/4885TSHR 101/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | TDP1 4232/4885L3MBTL1 2929/4885TSHR 227/4885 |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | FURIN, CD4, SI | TDP1 1403/4885L3MBTL1 2075/4885TSHR 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.